Background: Inflammation can modulate tumour growth and progression, and influence clinical response to treatment. We investigated the potential of circulating inflammatory proteins for response stratification of immune checkpoint inhibitor (ICI) therapy for advanced melanoma. Methods: Study subjects were 87 patients with unresectable stage III or IV cutaneous melanoma from the multiple centres across the United Kingdom (UK) and the Netherlands (NL) who received ipilimumab, nivolumab, or pembrolizumab, or a combination of ipilimumab and nivolumab. Serum samples were collected before and during ICI therapy at follow-up visits scheduled every third week over a 12-week period. We performed targeted quantification of 92 proteins involved in inflammation and tested for association of their pre-treatment and on-treatment levels, as well as longitudinal changes, with overall response rate, progression-free survival, and overall survival. Findings: We observed consistently higher pre-treatment...
Inflammation can modulate tumour growth and progression, and influence clinical response to treatment. We investigated the potential of circulating inflammatory proteins for response stratification of immune checkpoint inhibitor (ICI) therapy for advanced melanoma.
Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma / Rossi, Niccolò; Lee, Karla A; Bermudez, Maria V; Visconti, Alessia; Thomas, Andrew Maltez; Bolte, Laura A; Björk, Johannes R; de Ruijter, Laura Kist; Newton-Bishop, Julia; Harland, Mark; Shaw, Heather M; Harries, Mark; Sacco, Joseph; Board, Ruth; Lorigan, Paul; de Vries, Elisabeth G E; Segata, Nicola; Taams, Leonie; Papa, Sophie; Spector, Tim D; Nathan, Paul; Weersma, Rinse K; Hospers, Geke A P; Fehrmann, Rudolf S N; Bataille, Veronique; Falchi, Mario. - In: EBIOMEDICINE. - ISSN 2352-3964. - 83:(2022), pp. 10423501-10423512. [10.1016/j.ebiom.2022.104235]
Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma
Thomas, Andrew Maltez;Segata, Nicola;
2022-01-01
Abstract
Background: Inflammation can modulate tumour growth and progression, and influence clinical response to treatment. We investigated the potential of circulating inflammatory proteins for response stratification of immune checkpoint inhibitor (ICI) therapy for advanced melanoma. Methods: Study subjects were 87 patients with unresectable stage III or IV cutaneous melanoma from the multiple centres across the United Kingdom (UK) and the Netherlands (NL) who received ipilimumab, nivolumab, or pembrolizumab, or a combination of ipilimumab and nivolumab. Serum samples were collected before and during ICI therapy at follow-up visits scheduled every third week over a 12-week period. We performed targeted quantification of 92 proteins involved in inflammation and tested for association of their pre-treatment and on-treatment levels, as well as longitudinal changes, with overall response rate, progression-free survival, and overall survival. Findings: We observed consistently higher pre-treatment...| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S240545692200164X-main.pdf
Solo gestori archivio
Descrizione: Article in press
Tipologia:
Versione editoriale (Publisher’s layout)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
403.78 kB
Formato
Adobe PDF
|
403.78 kB | Adobe PDF | Visualizza/Apri |
|
1-s2.0-S2352396422004170-main.pdf
accesso aperto
Tipologia:
Versione editoriale (Publisher’s layout)
Licenza:
Creative commons
Dimensione
849.21 kB
Formato
Adobe PDF
|
849.21 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione
